Shares in Legend Biotech Corporation tumbled on Monday after the company announced the immediate resignation of its chief executive, Ying Huang. The stock fell more than 8% in after-hours trading on the Nasdaq, reflecting investor unease over the sudden leadership change at the US-listed biopharmaceutical firm.
Legend Biotech, which specialises in cell therapies for cancer, did not provide a detailed reason for Huang's departure. The company said its board has begun a search for a permanent successor, with an interim leadership structure to be announced in due course. Huang had been at the helm since 2020 and was widely credited with advancing the firm's pipeline, including its flagship CAR-T therapy, CARVYKTI, developed in partnership with Johnson & Johnson.
The news comes at a delicate time for the biotech sector, which has faced volatile market conditions amid rising interest rates and cautious investor sentiment towards early-stage drug developers. Legend Biotech's shares had already fallen by roughly 15% this year prior to yesterday's announcement, underperforming the broader Nasdaq biotech index.
For UK investors, the development carries particular weight. Legend Biotech is a significant holding in several actively managed pension funds and investment trusts focused on healthcare innovation. The company's ADRs are also held by UK-based institutional investors seeking exposure to the fast-growing CAR-T therapy market.
Analysts at Jefferies described the departure as 'unexpected and potentially disruptive', noting that Huang's leadership had been a key factor in the company's successful partnership with Johnson & Johnson. 'While the underlying science remains strong, a change at the top introduces execution risk,' they wrote in a note to clients.
The broader European biotech sector was largely flat on the day, with the STOXX Europe 600 Health Care index edging up 0.2%. However, the uncertainty surrounding Legend Biotech's succession plan could weigh on investor confidence in the near term, particularly if the search for a new CEO drags on.